GB2305606B - Drug delivery composition for the nasal administration of ICAM-1 - Google Patents

Drug delivery composition for the nasal administration of ICAM-1

Info

Publication number
GB2305606B
GB2305606B GB9700817A GB9700817A GB2305606B GB 2305606 B GB2305606 B GB 2305606B GB 9700817 A GB9700817 A GB 9700817A GB 9700817 A GB9700817 A GB 9700817A GB 2305606 B GB2305606 B GB 2305606B
Authority
GB
United Kingdom
Prior art keywords
icam
drug delivery
nasal administration
delivery composition
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB9700817A
Other versions
GB2305606A (en
GB9700817D0 (en
Inventor
Peter Watts
Lisbeth Illum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Services Ltd
Original Assignee
Danbiosyst UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danbiosyst UK Ltd filed Critical Danbiosyst UK Ltd
Publication of GB9700817D0 publication Critical patent/GB9700817D0/en
Publication of GB2305606A publication Critical patent/GB2305606A/en
Application granted granted Critical
Publication of GB2305606B publication Critical patent/GB2305606B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
GB9700817A 1994-07-26 1995-07-24 Drug delivery composition for the nasal administration of ICAM-1 Expired - Fee Related GB2305606B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9414966A GB9414966D0 (en) 1994-07-26 1994-07-26 Pharmaceutical compositions for the nasal administration of antiviral agents
PCT/GB1995/001735 WO1996003142A1 (en) 1994-07-26 1995-07-24 Drug delivery composition for the nasal administration of antiviral agents

Publications (3)

Publication Number Publication Date
GB9700817D0 GB9700817D0 (en) 1997-03-05
GB2305606A GB2305606A (en) 1997-04-16
GB2305606B true GB2305606B (en) 1998-08-05

Family

ID=10758832

Family Applications (2)

Application Number Title Priority Date Filing Date
GB9414966A Pending GB9414966D0 (en) 1994-07-26 1994-07-26 Pharmaceutical compositions for the nasal administration of antiviral agents
GB9700817A Expired - Fee Related GB2305606B (en) 1994-07-26 1995-07-24 Drug delivery composition for the nasal administration of ICAM-1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB9414966A Pending GB9414966D0 (en) 1994-07-26 1994-07-26 Pharmaceutical compositions for the nasal administration of antiviral agents

Country Status (7)

Country Link
EP (1) EP0773791A1 (en)
JP (1) JPH10506376A (en)
CA (1) CA2195639A1 (en)
FI (1) FI970331A (en)
GB (2) GB9414966D0 (en)
NO (1) NO970252D0 (en)
WO (1) WO1996003142A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879712A (en) * 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
DE69722594T2 (en) * 1996-03-06 2004-04-29 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield POWDERED MEDICINAL PRODUCT CONTAINING INTERCELLULAR ADHESIVE MOLECULE
GB9700624D0 (en) * 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
EP0994700A4 (en) * 1997-07-18 2000-10-18 Bayer Ag Methods of removing residual solvent from nasal drug delivery compositions
CA2308291A1 (en) * 1997-10-31 1999-05-14 Thierry Nivaggioli Controlled release compositions comprising gellan gum gels
AU751182B2 (en) * 1997-12-02 2002-08-08 Archimedes Development Limited Compositions for nasal administration
GB0015682D0 (en) * 2000-06-28 2000-08-16 Bristol Myers Squibb Co Sprayable wound care composition
GB2378383A (en) * 2001-06-06 2003-02-12 Gursharan Moonga Nasal delivery of pharmaceutical compositions in powder form
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
GB0328186D0 (en) 2003-12-05 2004-01-07 West Pharm Serv Drug Res Ltd Intranasal compositions
GB0403938D0 (en) * 2004-02-21 2004-03-24 West Pharm Serv Drug Res Ltd Chitosan containing solution
WO2008091588A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
DE102008007759B4 (en) 2007-12-04 2009-09-24 Atlantichem Gmbh Agent for preventing discoloration when washing textiles

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0314863A2 (en) * 1987-11-02 1989-05-10 Baylor College Of Medicine Use of ICAM-1 or its functional derivatives for the treatment of non-specific inflammation
EP0362531A1 (en) * 1988-09-01 1990-04-11 Bayer Corporation A human rhinovirus receptor protein that inhibits virus infectivity
WO1990005522A1 (en) * 1988-11-17 1990-05-31 Per Prisell Pharmaceutical preparation
WO1991006282A1 (en) * 1989-11-04 1991-05-16 Danbiosyst Uk Limited Small particle drug compositions
WO1993006842A1 (en) * 1991-10-02 1993-04-15 Boehringer Ingelheim Pharmaceuticals, Inc. Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma
WO1994000485A1 (en) * 1992-06-22 1994-01-06 Miles Inc. Multimeric forms of human rhinovirus receptor protein
WO1994027576A1 (en) * 1993-05-20 1994-12-08 Danbiosyst Uk Limited Nasal drug delivery composition containing nicotine

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0314863A2 (en) * 1987-11-02 1989-05-10 Baylor College Of Medicine Use of ICAM-1 or its functional derivatives for the treatment of non-specific inflammation
EP0362531A1 (en) * 1988-09-01 1990-04-11 Bayer Corporation A human rhinovirus receptor protein that inhibits virus infectivity
WO1990005522A1 (en) * 1988-11-17 1990-05-31 Per Prisell Pharmaceutical preparation
WO1991006282A1 (en) * 1989-11-04 1991-05-16 Danbiosyst Uk Limited Small particle drug compositions
WO1993006842A1 (en) * 1991-10-02 1993-04-15 Boehringer Ingelheim Pharmaceuticals, Inc. Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma
WO1994000485A1 (en) * 1992-06-22 1994-01-06 Miles Inc. Multimeric forms of human rhinovirus receptor protein
WO1994027576A1 (en) * 1993-05-20 1994-12-08 Danbiosyst Uk Limited Nasal drug delivery composition containing nicotine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Nature Vol. 344 1990. Marlin S et. al. pages 70-72 *
Trends in Biotechnology Vol. 9(8) 1991. ILLUM L pages 285 & 288 *

Also Published As

Publication number Publication date
GB2305606A (en) 1997-04-16
FI970331A0 (en) 1997-01-27
AU707462B2 (en) 1999-07-08
FI970331A (en) 1997-01-27
EP0773791A1 (en) 1997-05-21
CA2195639A1 (en) 1996-02-08
JPH10506376A (en) 1998-06-23
NO970252L (en) 1997-01-21
WO1996003142A1 (en) 1996-02-08
NO970252D0 (en) 1997-01-21
GB9414966D0 (en) 1994-09-14
GB9700817D0 (en) 1997-03-05
AU2988695A (en) 1996-02-22

Similar Documents

Publication Publication Date Title
GB2303064B (en) Medicament for nasal administration
HRP960300B1 (en) Inhaler for administration of blister-packed medicaments
IL116433A0 (en) Intravaginal drug delivery devices for the administration of 17B-oestradiol precursors
AU1529397A (en) Delivery system for localized administration of medicaments to the upper respiratory tract
HUP0002645A3 (en) Phospholipid containing pharmaceutical composition for treating sleep apnea and apparatus for enabling the administration thereof
IL127572A (en) Pharmaceutical composition and medicament for nasal administration
ZA965607B (en) Drug delivery compositions for improved stability of steroids
EP0769973A4 (en) Intrapulmonary drug delivery within therapeutically relevant inspiratory flow/volume values
HUP0000299A3 (en) Pharmaceutical formulations for sustained drug delivery
IL99521A0 (en) Nasal pharmaceutical composition
AU4534593A (en) Compositions and methods for enhanced drug delivery
EP0707471A4 (en) Novel therapeutic drug delivery systems
HUP0101293A3 (en) Aspb28-human insulin comprising pharmaceutical composition administered by inhalation and their use
GB9601969D0 (en) A system for the delivery of drugs and therapeutic agents
GB2305606B (en) Drug delivery composition for the nasal administration of ICAM-1
HK1042825A1 (en) Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
HUP9900751A3 (en) Stable pharmaceutical forms of administration containing parathormone
GB9418064D0 (en) Medicament administration inhaler
EP0817655A4 (en) Intrapulmonary delivery of hematopoietic drug
GB9014871D0 (en) Drug delivery system for administering growth factor
GB2333042B (en) Colonic delivery of weak acid drugs
ZA984832B (en) Pharmaceutical form for the administration of paclitaxel process for the preparation of a ready-to-use paclitaxel composition and use of this composition
GB9404293D0 (en) Drug delivery system
ZA9510787B (en) Intravaginal drug delivery devices for the administration of 17 beta-oestradiol precursors
GB9626012D0 (en) Colonic drug delivery composition

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20050724